AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

By PRNewswire On Dec 6, 2023

Collaboration to leverage BigHat’s Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie’s expertise in Oncology and Neuroscience to develop next-generation antibodies

AbbVie Inc. and BigHat Biosciences, announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat will utilize its Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high quality antibodies for multiple therapeutic targets.

“This collaboration further demonstrates our commitment to integrate AI/ML-based approaches in drug discovery and development, as we strive to accelerate our oncology and neuroscience pipeline, and deliver better medicines faster,” said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research at AbbVie. “We look forward to working with BigHat’s team to design novel antibody-based therapies that may help address persistent unmet needs faced by patients.”

Zenity Introduces the First Comprehensive AI Security Posture Management Solution to Govern Microsoft Fabric AI Skills

Dec 24, 2024

CodeGate Protects The Privacy Of Developers That Use AI Coding Assistants

Dec 24, 2024

AI is Only 30% Away From Matching Human-Level General Intelligence on GAIA Benchmark

Dec 24, 2024

Prev Next 1 of 40,670

Recommended AI News: ibex Partners with Sapling.ai for AI-Powered Messaging Tools

“We are thrilled to collaborate with AbbVie, a global leader in driving innovation in drug development, and look forward to employing our Milliner™ platform to help design next-generation therapeutic antibodies,” said Mark DePristo, CEO, BigHat. “Milliner™ allows rapid optimization of multiple key parameters including functionality and developability, to help deliver complex antibodies with improved characteristics faster.”

Under the terms of the agreement, BigHat will receive an upfront payment of $30 million and may be eligible to receive up to approximately $325 million in aggregate research and development milestones, with potential for further commercial milestones as well as tiered royalties on net sales.

[To share your insights with us, please write to sghosh@martechseries.com]